Dren Bio raises $350m for dibotatug clinical development
Dren Bio will use the capital to progress its broader pipeline in autoimmune disorders, immunology, neurology, and oncology.
Drug Development
FDA grants orphan drug status to Octant’s OCT-980 for RP
Arrowhead gains UK marketing authorisation for Redemplo
Regeneron agrees to $270m extension to supply Ebola medicine in US
China’s NMPA accepts Innovent application for sintilimab combo
Lunit and Summit to evaluate pathology platform for tumour analysis
